Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells.

Development 78

Development Drugs Manufacturing Immune Response 78

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Drug Discovery World

APRIL 11, 2024

We have noted that cancer patients can develop powerful anti-tumour immune responses that can result in complete cure of the disease and we call these patients ‘elite responders’. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 59

Research Immune Response Antibody Medicine 59

pharmaphorum

MAY 11, 2021

Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body. This makes the body into a “drug factory”, allowing for long-lasting medicines that allow for repeat redosing and can be administered easily by several routes.

RNA 98

RNA Drugs Protein Immune Response 98

Pharmaceutical Technology

APRIL 18, 2023

Innovation S-curve for the pharmaceutical industry HIV peptides is a key innovation area in pharmaceuticals HIV peptides are fragments derived from HIV envelope gp160 protein, the HIV matrix/capsid proteins, and the HIV gag, pol and env gene products. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

XTalks

FEBRUARY 19, 2024

In a recent study published by Weill Cornell Medicine in the Journal of Infectious Diseases , researchers have reported the potential of Moderna’s experimental mRNA vaccine in protecting adults against CMV, which could potentially also stop the transmission of the virus from mothers to their infants during pregnancy.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

AUGUST 26, 2020

The anti-inflammatory macrophages help in preventing an immune response from becoming dangerous, as seen with patients with autoimmune disease. This helps to ensure that inflammation naturally subsides after the initial immune response and promotes tissue repair.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

The Pharma Data

APRIL 15, 2022

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. Each serum was tested simultaneously for its neutralizing titer against recombinant SARS-CoV-2 (with USA-WA-1/2020 genetic backbone) bearing the wild-type SARS-CoV-2 spike protein and theOmicron spike.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics.

Gene 73

Gene Immune Response Manufacturing Gene Therapy 73

Drug Discovery World

MARCH 23, 2023

The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID) and led by Mark M Davis, Director of the Stanford Institute for Immunity, Transplantation and Infection and a professor of microbiology and immunology at Stanford University School of Medicine in California.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

XTalks

OCTOBER 12, 2021

The experimental arthritis vaccine was developed by researchers at the University of Toledo (UToledo) and is a major breakthrough for rheumatoid arthritis and other autoimmune diseases as well. The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

pharmaphorum

SEPTEMBER 30, 2020

This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. As expected, patients in the study formed two populations: those who had already mounted an immune response and those whose immune response was not yet adequate.

Antibody 135

Antibody Immune Response Trials Protein 135

Scienmag

JULY 6, 2021

Researchers at Karolinska Institutet in Sweden publish new findings in the journal Cancer Discovery showing how pharmacological activation of the protein p53 boosts the immune response against tumours. Given its ability to react […].

Immune Response 40

Immune Response Protein Development Research 40

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. MG: I am responsible for Agilent’s cancer segment. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?

Research 98

Research Protein Scientist Immune Response 98

XTalks

DECEMBER 20, 2021

Covovax is a recombinant protein-based vaccine and can be regarded as a more “traditional” vaccine as it isn’t genetic-based like mRNA or viral vector vaccines. Covovax is a protein subunit vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). Gavi secured 1.1

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 104

Vaccination Vaccine Research Immune Response 104

XTalks

DECEMBER 29, 2023

Reese, executive vice president of Research and Development at Amgen, in the company’s press release. Classified as a bispecific T-cell engager (BiTE molecule), tarlatamab consists of two essential parts: one binds to T-cells, vital in immune response, and the other targets cancer cells.

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

The Pharma Data

MARCH 8, 2022

While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. Like other members of this genus, SARS-CoV-2 is equipped with several molecular tools that allow it to evade recognition by the immune system.

Immune Response 52

Immune Response RNA Protein Genetics 52

pharmaphorum

FEBRUARY 24, 2021

The FDA has issued guidelines allowing for faster development of updated coronavirus vaccines, based on previously approved shots that have been tweaked to combat emerging variants of the SARS-CoV-2 virus. Manufacturers are also encouraged to study the response in previously vaccinated and unvaccinated people. “If

Vaccination 57

Vaccination Vaccine Immune Response Regulation 57

XTalks

MAY 24, 2024

Carbone, professor of internal medicine and director of the James Thoracic Oncology Center at the Ohio State University Medical Center, in a recent press release. Due to its aggressive nature, it has a poor prognosis and quickly develops resistance to chemotherapy. About 40 percent of patients saw significant shrinkage.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

pharmaphorum

AUGUST 31, 2021

Laronde is developing what it calls ‘endless’ RNA or eRNA, a circular form of the material that it says could have a number of advantages over other RNA-based therapeutics. The company has an ambitious goal of producing 100 eRNA medicines in the next decade.

RNA 52

RNA Protein Immune Response Medicine 52

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. These T cells are engineered to recognize various HIV proteins in a unique manner compared to previous experimental HIV vaccines. mRNA, 2) BG505 MD39.3

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Drug Discovery World

JANUARY 22, 2024

.” Andrea Bortolato , Director of Drug Discovery at SandboxAQ, will present: ‘Combining physics-based methods with AI solutions to maximise the probability of success and speed of drug discovery and development’. According to an article in Acta Pharmaceutica Sinica B , 90% of clinical drug development fails” 3.

Engineer 59

Engineer Immune Response Drugs Vaccination 59

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

Immune Response 101

Immune Response Development Research Protein 101

The Pharma Data

JANUARY 24, 2021

NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.

Development 52

Development Vaccination Vaccine Production 52

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. My initial exposure to medicine came through bench research.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

The Pharma Data

MAY 27, 2022

AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Vaccination 52

Vaccination Vaccine Immune Response Medicine 52

pharmaphorum

APRIL 28, 2021

. “Text mining was also able to highlight new insights into the mechanisms of pancreatic cancer’s immune evasion, which refers to cancer cells’ ability to evade an immune response” . Figure 1: Trending ‘Protein and Genomic’ terms with a semantic relationship to pancreatic cancer. About the author.

Immune Response 104

Immune Response Life Science Genome Genomics 104

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. chimeric receptor antigen [CAR] T cell) immune modulators (i.e. protein-based biologics) and vaccine treatments. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

JUNE 19, 2022

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. Known as “the guardian of the genome,” p53 is a class of proteins tasked with suppressing tumor development.

Drugs 52

Drugs Protein Immune Response Dermatology 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The joint development team is working on improving the temperature stability of the mRNA vaccine candidate and targeting a -20°C storage temperature for late-stage clinical trials and at launch.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . Our ambition is to develop life-changing treatments for patients.

Immune Response 52

Immune Response Licensing Licensing Sales 52

Delveinsight

AUGUST 26, 2021

Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

pharmaphorum

SEPTEMBER 8, 2021

Kadmon claimed approval for Rezurock (belumosudil) in July as a treatment for chronic graft versus host disease (GVHD) – a common and often fatal complication that can follow a bone marrow transplant and which occurs when the donated cells mount an immune response against the transplant recipient’s tissues and organs.

Drugs 52

Drugs Sales Immune Response Marketing 52